Obstructive Lung Disease Market Highlights
The use of drugs has emerged as an effective solution for the treatment of COPD and asthma, which largely contributes to the growth of the global obstructive lung disease market. The market is driven by the growing COPD and asthmatic patient population, as well as the FDA approval for novel products and its wide acceptance. Increasing government initiatives to control COPD and asthma further, fuel the growth of this market.
The global market of obstructive lung disease is expected to grow at a CAGR of approximately 8.5% during the forecast period 2017-2023.
Key Players
Some of key the players in the global obstructive lung disease market are,
- GlaxoSmithKline (GSK) (U.K)
- Novartis AG (Switzerland)
- Merck & Co. (U.S)
- Abbott Laboratories (U.S)
- Boehringer Ingelheim (Germany)
- AstraZeneca (U.K)
- Roche Holding AG (Switzerland)
- Teva Pharmaceutical Industries (Israel)
- Vectura Group (U.K)
- Pfizer Inc. (U.S)
- Mylan (U.S.)
- Aerovance Inc. (U.S.)
- Alkermes Inc. (U.S.)
- Almirall SA. (U.S.)
- Genentech Inc. (U.S.)
- Sepracor Inc. (U.S.)
- Skyepharma plc (U.S.)
Inquire for Sample Research Report https://www.marketresearchfuture.com/sample_request/5367
Obstructive Lung Disease Market Segmentation
The obstructive lung disease is segmented on the basis of disease type, product type, drug class, route of administration and end-users.
On the basis of disease type, the market is segmented into asthma, bronchiectasis, bronchitis and chronic obstructive pulmonary disease (COPD), and others
On the basis of product type, market is segmented into inhalers, and nebulizers. Inhalers are divided into Drug Powder Inhalers (DPIs), Metered Dose Inhalers (MDIs), Soft Mist Inhalers (SMIs). Moreover, nebulizers are divided into compressor nebulizers, ultrasonic nebulizers, and mesh nebulizers
On the basis of drug class, the market is segmented into combination drugs, leukotriene antagonists (LTA), inhaled corticosteroids (ICS), anticholinergics, short acting beta agonists (SABA), long acting beta agonists (LABA), and others. Furthermore, the combination products is divided into seretide/advair, symbicort, relvar/breo ellipta, flutiform, dulera, and others. Leukotriene Antagonists (LTA) is divided into singulair and others. Inhaled Corticosteroids (ICS) is divided into qvar, pulmicort, aerospan, flovent, and others. Anticholinergics is divided into Spiriva and Others. Short Acting Beta Agonists (SABA) is divided into proair, ventolin, and others.
On the basis of route of administration, market is segmented into oral, inhaler, intravenous, subcutaneous, and others
On the basis of end-user, the market is segmented into hospitals & diagnostic centers, academic institutes, pharmaceutical & biotechnology companies and others.
TABLE OF CONTENT
Chapter 1. Report Prologue
Chapter 2. Market Introduction
Chapter 3. Research Methodology
Chapter 4. Market Dynamics
Chapter 5. Market Factor Analysis
5.1 Porter’s Five Forces Analysis
5.1.1 Bargaining Power Of Suppliers
5.1.2 Bargaining Power Of Buyers
5.1.3 Threat Of New Entrants
5.1.4 Threat Of Substitutes
5.1.5 Intensity Of Rivalry
5.2 Value Chain Analysis
5.3 Investment Feasibility Analysis
5.4 Pricing Analysis
Chapter 6. Global Obstructive Lung Disease Market, By Disease Type
6.1 Introduction
6.2 Asthma
6.2.1 Market Estimates & Forecast, 2016 – 2023
6.3 Bronchiectasis
6.3.1 Market Estimates & Forecast, 2016 – 2023
6.4 Bronchitis
6.4.1 Market Estimates & Forecast, 2016 – 2023
6.5 Chronic Obstructive Pulmonary Disease (COPD)
6.5.1 Market Estimates & Forecast, 2016 – 2023
6.6 Others
Browse Complete Premium Research Report https://www.marketresearchfuture.com/reports/obstructive-lung-disease-market-5367
Chapter 7. Global Obstructive Lung Disease Market, By Product Type
7.1 Introduction
7.2 Inhalers
7.2.1 Market Estimates & Forecast, 2017 – 2023
7.2.2 Drug Powder Inhalers (DPIs)
7.2.2.1 Market Estimates & Forecast, 2017 – 2023
7.2.3 Metered Dose Inhalers (MDIs),
7.2.3.1 Market Estimates & Forecast, 2017 – 2023
To be continue…
Intended Audience
- Obstructive Lung Disease Drug Suppliers
- Obstructive Lung Disease Drug Manufacturers
- Obstructive Lung Disease Device Suppliers
- Obstructive Lung Disease Device Manufacturers
- Research And Development (R&D) Companies
- Medical Research Laboratories
- Academic Medical Institutes and Universities
Obstructive Lung Disease Market Regional Analysis
Global obstructive lung disease consists of regions namely the Americas, Europe, Asia Pacific, and the Middle East and Africa.
North America together dominates the global asthma and COPD market followed by the European market. Rising prevalence of asthma and COPD due to pollution, changing lifestyle, and the entry of generic and novel therapies in the market.
Asia Pacific is anticipated to be the fastest growing market over the forecast period. Emerging economies such India, China due to industrialization, demographic changes, and urbanization are witnessing increased levels of pollution, thus favoring the rising prevalence of asthma and COPD population.
Avail Discount at https://www.marketresearchfuture.com/check-discount/5367
About Market Research Future: MRFR team have supreme objective to provide the optimum quality market research and intelligence services to our clients. In order to stay updated with technology and work process of the industry, MRFR often plans & conducts meet with the industry experts and industrial visits for its research analyst members.
Contact:
Office No. 528, Amanora Chambers
Magarpatta Road, Hadapsar, Pune
+1 646 845 9312
Email: sales@marketresearchfuture.com
Your information will never be shared with any third party.